Inhibition of poly(ADP-ribose) polymerase attenuates cerebral vasospasm after subarachnoid hemorrhage in rabbits

被引:51
|
作者
Satoh, M
Date, I
Nakajima, M
Takahashi, K
Iseda, K
Tamiya, T
Ohmoto, T
Ninomiya, Y
Asari, S
机构
[1] Okayama Univ, Sch Med, Dept Neurol Surg, Okayama 7008558, Japan
[2] Okayama Univ, Sch Med, Dept Mol Biol & Biochem, Okayama 7008558, Japan
[3] Okayama Univ, Sch Med, Fac Hlth Sci, Okayama 7008558, Japan
关键词
nitric oxide synthase; subarachnoid hemorrhage; vasospasm; rabbits;
D O I
10.1161/01.STR.32.1.225
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and Purpose-Poly(ADP-ribose) polymerase (PARP) is important in modulating inflammation, which has been implicated in cerebral vasospasm after subarachnoid hemorrhage (SAH). We investigated the role of PARP in vasospasm using 3-aminobenzamide (3-AB), a PARP inhibitor, in a rabbit model. Methods-Twenty-four New Zealand White rabbits were divided into 4 groups: (1) no treatment (control group, n=6); (2) blood injection without pretreatment (SAH-only group, n=6); (3) blood injection with pretreatment by vehicle (SAH+vehicle group, n = 6); and (4) blood injection with pretreatment by 3-AB (SAH+3-AB group, n=6). We used the single-hemorrhage model of SAH, injecting autologous arterial blood into the cisterna magna. Angiography was performed before (baseline) and after (day 2) SAH, and the diameter of the basilar artery (BA) was measured. Animals were euthanatized after the second angiogram. After perfusion and fixation, the brains were cut into sections for hematoxylin and eosin and immunohistochemical staining for poly(ADP-ribosyl)ation. Results-In the control group, there were no differences in the BA lumen caliber between baseline and day 2 (96.8+/-10.4%). Cerebral vasospasm in the SAH+3-AB group (88.2+/-6.2%) was remarkably attenuated in comparison with that in the SAM-only group (64.9+/-8.0%) and the SAH+vehicle group (65.6+/-10.8%). The BA in the SAH+3-AB group showed less corrugation of the tunica elastica interna than that in the SAH-only and SAH+vehicle groups. Staining for poly(ADP-ribosyl)ation was markedly inhibited in smooth muscle and adventitial cells of the BA in the SAH+3-AB group compared with other groups. Conclusions-Inhibiting ADP-ribosylation attenuates cerebral vasospasm after SAH in rabbits, and PARP activation may play an important role in the development of cerebral vasospasm.
引用
收藏
页码:225 / 230
页数:6
相关论文
共 50 条
  • [31] THE EFFECT OF THE INHIBITION OF POLY (ADP-RIBOSE) POLYMERASE ON RADIATION SENSITIVITY
    GEORGE, AM
    LUNEC, J
    HEDGES, M
    SUN, GQ
    SABOVLJEV, SA
    CRAMP, WA
    BRENNAN, S
    LEWIS, PD
    WHISH, WJD
    HUNT, B
    INTERNATIONAL JOURNAL OF RADIATION BIOLOGY, 1983, 44 (01) : 107 - 108
  • [32] Poly(ADP-ribose) polymerase inhibition: past, present and future
    Curtin, Nicola J.
    Szabo, Csaba
    NATURE REVIEWS DRUG DISCOVERY, 2020, 19 (10) : 711 - 736
  • [33] POLY(ADP-RIBOSE) POLYMERASE AND DNA
    YOSHIHARA, K
    SEIKAGAKU, 1981, 53 (07): : 528 - 534
  • [34] Poly(ADP-Ribose) Polymerase Inhibitors
    Garon, Edward B.
    Dubnett, Steven M.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S455 - S456
  • [35] INHIBITION OF THE ADP-RIBOSE POLYMERIZATION REACTION CATALYZED BY POLY(ADP-RIBOSE)POLYMERASE WITH AGMATINE-(ADP-ROBOSE)
    PACHECORODRIGUEZ, G
    ALVAREZGONZALEZ, R
    FASEB JOURNAL, 1994, 8 (07): : A1280 - A1280
  • [36] Poly(ADP-ribose) polymerase and aging
    Burkle, A
    EXPERIMENTAL GERONTOLOGY, 1998, 33 (06) : 519 - 523
  • [37] Trapping Poly(ADP-Ribose) Polymerase
    Shen, Yuqiao
    Aoyagi-Scharber, Mika
    Wang, Bing
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2015, 353 (03): : 446 - 457
  • [38] Poly(ADP-ribose) polymerase inhibitors
    Southan, GJ
    Szabó, C
    CURRENT MEDICINAL CHEMISTRY, 2003, 10 (04) : 321 - 340
  • [39] Role of superoxide in poly(ADP-ribose) polymerase upregulation after transient cerebral ischemia
    Narasimhan, P
    Fujimura, M
    Noshita, N
    Chan, PH
    MOLECULAR BRAIN RESEARCH, 2003, 113 (1-2): : 28 - 36
  • [40] Current role of poly(ADP-ribose) polymerase inhibitors: which poly(ADP-ribose) polymerase inhibitor and when?
    Vanacker, Helene
    Romeo, Clemence
    Ray-Coquard, Isabelle
    CURRENT OPINION IN ONCOLOGY, 2019, 31 (05) : 394 - 403